Mucinex Exploratory Cold Study

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Reckitt Benckiser Inc.; Reckitt Benckiser LLC
• Treatments: Chlorpheniramine, phenylpropanolamine drug combination; Guaifenesin; Phenylpropanolamine

Criteria

Inclusion Criteria:

• common cold symptoms

• meet symptom severity

• females of child-bearing potential must have negative pregnancy test and use effective birth control

Exclusion Criteria:

• chronic respiratory conditions

• significant heart, kidney, liver, or lung disease, uncontrolled hypertension or diabetes, cystic fibrosis, thyroid disorder

• pregnant or lactating

• known malignancy

• participation in any other clinical trial within 30 days of baseline

• related to another enrolled patient or persons involved directly or indirectly with the conduct of this study